Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test

This document is a response to public comments on the MolDX EndoPredict Breast Cancer Gene Expression Test (LCD L37295) and does not itself define clinical coverage criteria. It records the comment period (2020-05-28 to 2020-07-12), the LCD notice start date (2021-05-27), and LCD effective date (2021-07-11); refer to LCD L37295 for specific indications, limitations, documentation, and frequency rules.

"This document contains responses to comments regarding the MolDX EndoPredict Breast Cancer Gene Expression Test and does not itself establish clinical coverage criteria; coverage is governed by LCD..."

Sign up to see full coverage criteria, indications, and limitations.